An interventional study of CART-I plus and Polysomnography in Obstructive Sleep Apnea and Obstructive Sleep Apnea-hypopnea, sponsored by Sky Labs. Recruiting at 1 site in Korea, Republic of. Open to female participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-26.
Sponsored by Sky Labs · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Sleep Apnea, Obstructive with a site in Korea, Republic of — 6 open to participants now, 6 under way, 1 of them phase 3. Sleep Apnea, Obstructive · Korea, Republic of.
Among the 16 studies in Sleep Apnea, Obstructive with a site in Korea, Republic of, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is one of 7 with no phase, and was the 13th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →6 of the 16 studies in Sleep Apnea, Obstructive with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Korea, Republic of, United States, Australia and 8 more countries
Ages 18+
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 22–85
Seoul National University Hospital · Sites in Korea, Republic of
Ages 18–70
Zeng Changhao · Sites in Korea, Republic of
Ages 18+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 19 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 107 is above the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 55 across the 10 interventional studies, 124 across the 6 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 16 have an industry lead sponsor. The 9 most frequent:
Sky Labs is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Sky Labs has 1 study filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
1 of the studies in Sleep Apnea, Obstructive with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06792188Seoul National University HospitalSmartwatch-Based AI Model for OSA Prediction (SWOSA) | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Sleep Apnea, Obstructive with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective is to enhance the reliability of the algorithm to match that of Level 1 polysomnography by leveraging the diverse data obtained from Level 1 polysomnography to refine the deep learning algorithm.
Patients undergoing Level 1 polysomnography are equipped with the CART-I PLUS device, for collecting polysomnography data alongside concurrent photoplethysmography (PPG) signals.
The collected data is categorized into apnea, hypopnea, and normal segments based on the polysomnography results. Utilizing the PPG and accelerometer (ACC) signals from the CART-I PLUS, metrics such as SaO2 (oxygen saturation), respiratory rate, heart rate (HR), heart rate variability (HRV), and body movement are calculated for each segment. These metrics, along with the PPG and ACC signals, are then used to develop a deep learning model that classifies the segments into apnea, hypopnea, or normal.
Participants are divided into training and validation sets. The deep learning model is trained on data from the participants in the training set, and its performance is evaluated using the validation set.
The algorithm is constructed using convolutional neural networks (CNN), recurrent neural networks (RNN), attention mechanisms, and other advanced techniques recognized for their efficacy in classification tasks, specifically for identifying apnea, hypopnea, and normal segments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients scheduled for Level 1 polysomnography at a sleep center who meet all of the following criteria:
Exclusion Criteria:
For patients undergoing Level 1 polysomnography, simultaneous collection of photoplethysmography (PPG) signals and polysomnography data is performed using the CART-I PLUS device.
Device: CART-I plus · Device: Polysomnography
CART-I PLUS collects signals in two ways: ECG: Utilizes the metal on the inner and outer sides as electrodes to detect subtle electrical changes resulting from the contraction and relaxation of the heart muscle. PPG: Emits LED light into the blood vessels inside the finger and collects the signal reflected by the blood flow, thereby gathering data on the pulse and functional oxygen saturation (SpO2) of arterial hemoglobin. In this clinical trial, PPG signals will be continuously collected during the polysomnography using the PPG method.
In polysomnography, the following data are collected: Electrocardiogram (ECG), Electroencephalogram (EEG), Electromyogram (EMG), Electrooculogram (EOG), Oxygen Saturation (SpO2) Respiratory Analysis, Body Position Monitoring
Accuracy of the algorithm and the 95% confidence interval
Present the accuracy of the algorithm and the 95% confidence interval. If the lower bound of the 95% confidence interval exceeds a minimum accuracy of 0.85, it is considered clinically significant.
Time frame: 11 hours
Accuracy and 95% confidence intervals for each interval
Present the accuracy and 95% confidence intervals for each interval. Additionally, precision, recall, ROC curve, and AUC may be presented. The performance comparison between algorithms will use the bootstrap method, and a p-value less than 0.05 will be considered statistically significant.
Time frame: 11 hours
Started Oct 2022 (actual). Primary completion is estimated for Apr 2025, 30 months after the start.
Of 118 industry-sponsored interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 30 months is above that.
Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sky Labs